- Home
- CQP vs RVMD Comparison
CQP vs RVMD Comparison
Compare CQP & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CQP | RVMD |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3B | 30.1B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | CQP | RVMD |
|---|---|---|
| Price | $65.91 | $189.06 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $60.43 | ★ $140.84 |
| AVG Volume (30 Days) | 139.3K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $10,758,000,000.00 | N/A |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $1.27 | $533.02 |
| P/E Ratio | $922.29 | ★ N/A |
| Revenue Growth | ★ 23.60 | N/A |
| 52 Week Low | $49.53 | $34.00 |
| 52 Week High | $70.64 | $193.83 |
Technical Indicators
Market Signals| Indicator | CQP | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 54.50 |
| Support Level | $62.10 | $93.39 |
| Resistance Level | $66.80 | $193.83 |
| Average True Range (ATR) | 1.65 | 6.04 |
| MACD | 0.22 | -1.97 |
| Stochastic Oscillator | 79.58 | 31.14 |
Price Performance
Historical ComparisonAbout CQP Cheniere Energy Partners LP
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.